



EVALUATION OF POTENTIALLY INAPPROPRIATE
PRESCRIBING AMONG HOSPITALISED GERIATRIC
PATIENTS: PREVALENCE, PREDICTORS,
ASSOCIATION WITH QUALITY OF LIFE AND
IMPACT OF A MULTIFACETED INTERVENTION ON
HEALTHCARE PROVIDERS' KNOWLEDGE AND
PRACTICE IN SELECTED PAHANG HOSPITALS

BY

MUHAMMAD EID AKKAWI

A thesis submitted in fulfilment of the requirement for the
degree of Doctor of Philosophy in Pharmaceutical Sciences
(Pharmacy Practice)

Kulliyyah of Pharmacy
International Islamic University Malaysia

OCTOBER 2018

ABSTRACT

Background: Potentially inappropriate prescribing (PIP) is a global phenomenon among geriatric patients. The term PIP refers to either potentially inappropriate medication (PIM) or potentially prescribing omission (PPO). PIP is an underestimated problem in Malaysia with a paucity of published data in regards to this issue. **Methods:** This is a pre-test versus post-test interventional study. The pre-intervention phase was a cross-sectional study that evaluated the prevalence of PIP among hospitalised geriatric patients upon admission and its association with the patients' health-related quality of life (HRQOL). The impact of hospitalisation on PIP was also assessed by comparing the prevalence of PIP before and after the hospitalisation. A multifaceted intervention consisted of academic detailing and a smartphone app. (Plus65 Med[®]) was delivered to hospital healthcare providers (HCPs), namely physicians and clinical pharmacist. The impact of this intervention on HCPs' knowledge and practice regarding PIP was then assessed. **Results:** The study found that 58.5% of the involved patients had at least one PIP on admission as identified by the STOPP/START criteria version 2. The most common PIMs were medications that increase risk of falls, and those used in patients with persistent postural hypotension; the use of full dosage of proton pump inhibitors for more than 8 weeks in patients with uncomplicated peptic ulcer and the use of metformin in patients with creatinine clearance < 30 mL/min. The most common PPOs were; the omission of vitamin D supplements in patients with a history of falls, angiotensin-converting enzyme (ACE) inhibitors in patients with documented coronary artery diseases (CAD), heart failure or in diabetic patients with renal failure. No association was found between the presence of PIM (or PPO) with any aspects of the patients' HRQOL. Hospitalisation significantly reduced the prevalence of PIMs from 33.3% at admission to 27% at discharge ($p = 0.004$) but it did not affect the PPOs. No significant changes found in the overall prevalence of PIPs and pattern of PIM or PPO, where hospitalisation did not significantly reduce the prevalence rates of any of individual STOPP or START criteria. Majority of hospital HCPs (67.1%) had inadequate knowledge coupled with low confidence regarding prescribing in geriatric patients, and participants who rated themselves as more confident in prescribing for geriatric patients had significantly higher knowledge scores than those with less confidence ($p = 0.02$). It was found that 60% of the respondents had never heard of geriatric-specific prescribing criteria and only 7.3% of them had ever used such criteria. Lack of formal education on prescribing for the elderly was cited by 78% of the participants as real barrier to appropriate prescribing in geriatric patients. The multifaceted intervention was effective in increasing the overall HCPs' knowledge score ($p = 0.007$) and the number of HCPs who scored above the median point ($p = 0.001$). Moreover, the intervention significantly reduced the prevalence of PPOs among discharged patients ($p = 0.015$) and the two most common PPOs that were seen before intervention (i.e., omission of vitamin D and ACE inhibitors) were significantly lower in the intervention group ($p_1 = 0.001$ and $p_2 = 0.03$). However, the intervention did not significantly affect the prevalence or pattern of PIMs. **Conclusion:** The study showed that the applied intervention reduced the inappropriately omission of beneficial medications which might have a significant clinical impact on the patients by reducing the incidence of new fractures and by preventing the recurrence of CAD events.

خلاصة البحث

إن الوصف غير المناسب (و.غ.م) للأدوية هو أمر شائع عند المسنين، وهذه الظاهرة لم تحظَ بالدراسة الكافية في ماليزيا. تحوّرت هذه الدراسة نسبة انتشار الـ (و.غ.م) عند المرضى المسنين المسعّفين إلى المشفى وتأثير هذا على مستوى جودة حياتهم وكذلك تأثير الاستشفاء على هذه الظاهرة إضافة إلى قياس مدى معرفة الطاقم الطبي للوصف المناسب للأدوية عند المسنين. وجدت الدراسة أن 58.5% كان لديهم و.غ.م واحد على الأقل عند دخول المشفى وذلك بحسب النسخة الثانية من معايير STOPP/START. أكثر أدوية وصفت بشكل غير مناسب كانت الموسّعات الوعائية عند مرضى هبوط الضغط الانتصابي، ومثبطات مضخة البروتون لأكثر من ثمانية أسابيع، والميتفورمين عند مرضى تصفيتهم الكلوية أقل من 30 مل/د. بينما كان أشهر الأدوية التي حذفت بشكل غير مناسب الفيامين د عند المرضى الذين لديهم تاريخ سقوط، وحذف مثبطات الخميرة المحولة للأنجيوتنسين عند مرضى الشرايين الإكليلية أو مرضى السكري المصاحب لأذية كلوية. لم يكن هناك ارتباط بين الـ و.أ.غ و مستوى جودة حياة المرضى. خفض الاستشفاء من وصف الأدوية غير المناسبة من 33.3% إلى 27% ($p = 0.04$) لكنه لم يؤثر على حذف الأدوية المناسبة. وجدت الدراسة أن 67.1% من أفراد الطاقم الطبي لديهم معرفة متواضعة مع ضعف ثقة حول وصف الأدوية للمسنين، وكان هناك ارتباط وثيق بين درجة الثقة ومدى المعرفة ($p = 0.02$). أيضا 60% من المشاركين لم يسمعوا عن المعايير الخاصة بوصف الأدوية عن المسنين مثل Beers و STOPP/START و فقط 7.3% منهم استخدموا مثل هذه المعايير في حياتهم. أشار 78% من المشاركين إلى أن نقص التعليم والتدريب الرسميين حول الأدوية عند المسنين هو أحد العوائق نحو وصف الأدوية بشكل مناسب عند هذه الفئة العمرية. قمنا بتطوير تطبيق للهاتف الجوال يحوي معايير STOPP/START واسميناه (Plus65 Med©) ومن ثم قدمناه للطاقم الطبي في المشفى مع سلسلة من المحاضرات التعليلية حول وصف الأدوية عند المسنين. تم تقييم فعالية هذه المداخلة على معرفة وممارسة الطاقم الطبي. أثبتت المداخلة فعاليتها في تحسين معرفة الطاقم الطبي حول الوصف المناسب للأدوية عند المسنين ($p = 0.007$) وكذلك كانت فعالة في التخفيف من حذف الأدوية المناسبة ($p = 0.015$) وخصوصاً تلك التي كانت منتشرة بكثرة قبل المداخلة لكن المداخلة لم تنجح في خفض وصف الأدوية غير المناسبة. بالحصلة: إن المداخلة المجرأة زاد من وصف بعض الأدوية المفيدة للمرضى والتي قد تقيهم من حدوث كسور جديدة أو حوادث قلبية إكليلية في المستقبل.

APPROVAL PAGE

The thesis of Muhammad Eid Akkawi has been approved by the following:

Mohamad Haniki Nik Mohamad
Supervisor

Mohd Aznan Md Aris
Co-Supervisor

Samsul Draman
Internal Examiner

Mohamad Azmi Bin Ahmad Hassali
External Examiner

Noorizan Abd Aziz
External Examiner

Mohammed Imad Al-Deen Mustafa
Chairman

DECLARATION

I hereby declare that this thesis is the result of my own investigations, except where otherwise stated. I also declare that it has not been previously or concurrently submitted as a whole for any other degrees at IIUM or other institutions.

Muhammad Eid Akkawi

Signature

Date

INTERNATIONAL ISLAMIC UNIVERSITY MALAYSIA

**DECLARATION OF COPYRIGHT AND AFFIRMATION OF
FAIR USE OF UNPUBLISHED RESEARCH**

**EVALUATION OF POTENTIALLY INAPPROPRIATE
PRESCRIBING AMONG HOSPITALISED GERIATRIC
PATIENTS: PREVALENCE, PREDICTORS, ASSOCIATION
WITH QUALITY OF LIFE AND IMPACT OF A
MULTIFACETED INTERVENTION ON HEALTHCARE
PROVIDERS' KNOWLEDGE AND PRACTICE IN SELECTED
PAHANG HOSPITALS**

I declare that the copyright of this thesis is jointly owned by the student and IIUM.

Copyright © 2018 Muhammad Eid Akkawi and International Islamic University Malaysia. All rights reserved.

No part of this unpublished research may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise without prior written permission of the copyright except as provided below

1. Any material contained in or derived from this unpublished research may be used by others in their writing with due acknowledgement.
2. IIUM or its library will have the right to make and transmit copies (print or electronic) for institutional and academic purposes.
3. The IIUM library will have the right to make, store in a retrieved system and supply copies of this unpublished research if requested by other universities and research libraries.

By signing this form, I acknowledged that I have read and understand the IIUM Intellectual Property Right and Commercialization policy.

Affirmed by Muhammad Eid Akkawi

.....
Signature

.....
Date

ACKNOWLEDGEMENTS

All praise and glory are due to my Lord, the Almighty, who eased this strenuous journey to me and showered me with His blessings to reach this destination.

My utmost thanks are to my great supervisor, Assoc. Prof. Dr. Mohamad Haniki Nik Mohamad for his unlimited support throughout this project, and from whom I learnt what being a real scholar means.

I would like also to thank my second advisor, Assoc. Prfo. Dr. Mohd Aznan Md Aris for his valuable comments and input on this work.

My wholehearted thanks to my beloved family members for their support and prayers; my father, my mother, my brother and my first teacher, sister who taught me the ABCs.

Last but not least, my deepest heart thanks to my dear wife, Raghad for her unconditional love and who was patient enough with me to make this dream come true.

TABLE OF CONTENTS

Abstract	ii
Arabic Abstract	iii
Approval Page	iv
Declaration	v
Acknowledgements	vii
Table of contents	viii
List of Tables	xiii
List of Figures	xv
List of Abbreviations	xvi
CHAPTER ONE: INTRODUCTION	1
1.1 Background of The Study	1
1.2 Definition of an Elderly Person	2
1.3 Changes with Ageing.....	2
1.3.1 Changes in Pharmacokinetics of Drugs in Elderly People	2
1.3.1.1 Absorption.....	3
1.3.1.2 Distribution	4
1.3.1.3 Metabolism	5
1.3.1.4 Elimination.....	6
1.3.2 Changes in Pharmacodynamics of Drugs in Elderly People	7
1.3.2.1 Central Nervous System	7
1.3.2.2 Cardiovascular System.....	9
1.4 Potentially Inappropriate Prescribing	11
1.4.1 Misprescribing	11
1.4.2 Overprescribing	12
1.4.3 Underprescribing	12
1.4.4 Prescribing in Geriatric Patients and Predisposing Factors of PIP.....	12
1.4.5 Negative Outcomes of PIP.....	14
1.4.5.1 PIP and Health-Related Quality of Life.....	15
1.4.6 Detection of PIP.....	16
1.4.6.1 Implicit Criteria.....	16
1.4.6.2 Explicit Criteria.....	18
1.4.7 The clinical Outcomes of Applying the STOPP/START Criteria.....	23
1.5 Polypharmacy	23
1.6 Problem Statement.....	25
1.7 Rationale of The Study	25
1.8 Novelty of The Study.....	26
1.9 Study Objectives	26
1.9.1 General Objective	26
1.9.2 Specific Objectives	26
1.10 Study Hypothesis	27
1.11 Study Site.....	27
1.12 Study Flow.....	27

CHAPTER TWO: LITERATURE REVIEW	30
2.1 Introduction.....	30
2.2 Interventional Approaches To Optimise Prescribing In Geriatric Patients	31
2.2.1 Pharmacist’s Intervention	31
2.2.1.1 Impact of Pharmacist’s in Acute Healthcare Setting	32
2.2.1.2 Impact of Pharmacist’s Intervention in Ambulatory Healthcare Settings	33
2.2.1.3 Impact of Pharmacist’s Intervention in Nursing Homes.....	35
2.2.2 A Multidisciplinary Medical Team Approach.....	36
2.2.3 Education of Healthcare Providers	37
2.2.4 Clinical Decision Support Software	42
2.2.5 Smartphone Application	44
CHAPTER THREE: THE PREVALENCE, PATTERN AND PREDICTORS OF POTENTIALLY INAPPROPRIATE PRESCRIBING AMONG HOSPITALISED GERIATRIC PATIENTS.....	45
3.1 Introduction	45
3.2 Methods.....	46
3.2.1 Study Design and setting	46
3.2.2 Sample Size	46
3.2.3 Study Population.....	47
3.2.3.1 Inclusion Criteria	47
3.2.3.2 Exclusion Criteria	47
3.2.4 Ethical Considerations	47
3.2.5 Data Collection	48
3.2.6 Statistical Analysis.....	49
3.3 Results.....	50
3.3.1 Characteristics of The Study Population	50
3.3.2 Past Medical History and On-admission Medications.....	51
3.3.3 Potentially Inappropriate Medications.....	52
3.3.4 Potentially Prescribing Omissions Among the Hospitalised Patients.....	55
3.4 Discussion.....	58
3.5 Conclusion.....	65
CHAPTER FOUR: POTENTIALLY INAPPROPRIATE PRESCRIBING AND HEALTH-RELATED QUALITY OF LIFE.....	67
4.1 Introduction	67
4.2 Methods.....	68
4.2.1 Study Design and Setting.....	68
4.2.2 Study Population.....	68
4.2.3 Potentially Inappropriate Prescribing and Polypharmacy	68
4.2.4 Assessment of the Health-Related Quality of Life	68
4.2.5 Statistical Analysis.....	69
4.3 Results.....	70
4.3.1 Patients Characteristics	70
4.3.2 Potentially Inappropriate Prescribing	72
4.3.3 Health-Related Quality of Life	72
4.3.4 Predictors of Health-Related Quality of Life HRQOL.....	75
4.4 Discussion.....	79

4.5 Conclusion.....	84
---------------------	----

CHAPTER FIVE: THE IMPACT OF HOSPITALISATION ON POLYPHARMACY AND POTENTIALLY INAPPROPRIATE PRESCRIBING AMONG GERIATRIC PATIENTS.....85

5.1 Introduction.....	85
5.2 Methods.....	86
5.2.1 Study Design and Setting.....	86
5.2.2 Study Population and Data Collection.....	86
5.2.3 Sample Size	87
5.2.4 Statistical Analysis.....	88
5.3 Results.....	89
5.3.1 Patients Characteristics	89
5.3.2 The Impact of The Hospitalisation on The Number of Prescribed Medications and The Prevalence of Polypharmacy.....	90
5.3.3 The Impact of Hospitalisation on Potentially Inappropriate Medications	91
5.3.4 The Impact of Hospitalisation on Potentially Prescribing Omissions	93
5.4 Discussion.....	95
5.5 Conclusion.....	98

CHAPTER SIX: ASSESSMENT OF THE KNOWLEDGE OF HOSPITAL HEALTHCARE PROVIDERS REGARDING APPROPRIATE PRESCRIBING IN GERIATRIC PATIENTS99

6.1 Introduction.....	99
6.2 Methods.....	100
6.2.1 Questionnaire Development	100
6.2.2 Questionnaire Validation	100
6.2.2.1 Content Validity.....	100
6.2.2.2 Reliability Test.....	101
6.2.3 The Final Questionnaire	101
6.2.4 Study Design and Setting.....	102
6.2.5 Study Population.....	103
6.2.6 Statistical Analysis.....	103
6.3 Results.....	103
6.3.1 Content Validity.....	103
6.3.2 Reliability	104
6.3.3 Sample Characteristics.....	105
6.3.4 Confidence and Usage of Medical Resources	106
6.3.5 Knowledge Score of the Healthcare providers	107
6.3.6 Barriers to Appropriate Prescribing for Geriatric patients	109
6.4 Discussion.....	110
6.5 Conclusion.....	115

CHAPTER SEVEN: THE IMPACT OF A MULTIFACETED INTERVENTION ON THE KNOWLEDGE OF HEALTHCARE PROVIDERS ABOUT PRESCRIBING FOR GERIATRIC PATIENTS116

7.1 Introduction.....	116
7.2 Methods.....	117

7.2.1 Study Design and Setting.....	117
7.2.2 The Intervention.....	117
7.2.2.1 Designing the intervention framework	117
7.2.2.2 Implementation of the designed intervention	122
7.2.3 Statistical Analysis.....	124
7.3 Results.....	125
7.3.1 Characteristics of The Participants	125
7.3.2 Knowledge Score of the Participants Before and After the Intervention.....	126
7.3.3 The Healthcare providers' Feedback on Plus65 Med [®]	127
7.4 Discussion.....	127
7.5 Conclusion.....	130

CHAPTER EIGHT: THE IMPACT OF A MULTIFACETED INTERVENTION FOR HEALTHCARE PROVIDERS ON PRESCRIBING INAPPROPRIATE MEDICATION FOR HOSPITALISED GERIATRIC PATIENTS.....131

8.1 Introduction.....	131
8.2 Methods.....	132
8.2.1 Study Design and Setting.....	132
8.2.2 Study population and data collection.....	132
8.2.3 Sample Size	133
8.2.4 The Intervention.....	133
8.2.5 Statistical Analysis.....	134
8.3 Results.....	134
8.3.1 Characteristics of The Study Population	134
8.3.2 Impact of the Intervention on Potentially Inappropriate Prescribing ..	135
8.4 Discussion.....	141
8.5 Conclusion.....	144

CHAPTER NINE: STUDY SUMMARY146

9.1 Overall Discussion And Conclusion.....	146
9.2 Limitations.....	150
9.3 Future Work.....	151

REFERENCES.....152

Appendix I: Informed consent form, English version	176
Appendix II: Informed consent form, Malay version.....	177
Appendix III: Participant information sheet, English version	178
Appendix IV: Participant information sheet, Malay version	181
Appendix V: Data collection sheet.....	184
Appendix VI: Katz Index of Independence in Activities of Daily Living (ADL)	188
Appendix VII: The English version for Malaysia of EQ-5D-3L instrument....	189
Appendix VIII: The Malay version of EQ-5D-3L instrument.....	192
Appendix IX: Malaysian predicted values for 243 EQ-5D-3L health states (N3 VAS model).....	196
Appendix X: The Permission to use EQ-5D-3L	198

Appendix XI: The Permission to use Ramaswamy's Questionnaire.....	199
Appendix XII: The Validated Questionnaire	200
Appendix XIII: The Permission to use the figures of Michie et al, 2011	204
Appendix XIV: The STOPP/START criteria version 2	205
Appendix XV: Publications.....	212

LIST OF TABLES

<u>Table No.</u>	<u>Page No.</u>
Table 1.1: Medication Inappropriate Index	17
Table 2.1: Summary of number of studies which implemented educational interventions to optimise prescribing in geriatric patients	39
Table 3.1: Characteristics of the study population (N = 540)	50
Table 3.2: Patients' past medical history and medications	51
Table 3.3: Potentially Inappropriate Medications PIMs identified by the STOPP criteria (N = 540)	53
Table 3.4: Predictors of having potentially inappropriate medication (PIM)	55
Table 3.5: Potentially Prescribing Omissions by the START criteria (N = 540)	56
Table 3.6: Predictors of having potentially prescribing omission PPO	58
Table 4.1: Patients characteristics (N = 502)	71
Table 4.2: Comparison of EQ-5D results between patients with and without potentially inappropriate prescribing	74
Table 4.3: Comparison of Patients' HRQOL between patients based on their characteristics	76
Table 4.4: Correlation between HRQOL and continuous variables	77
Table 4.5: Predictors of EQ-5D index	78
Table 4.6: Predictors of EQ-VAS	79
Table 5.1: The McNemar's hypothetical two-way table	87
Table 5.2: Characteristics of the study population (N = 240)	89
Table 5.3: Medications, PIMs and PPOs pre-and post-hospitalisation among the hospitalised patients (N = 240)	90
Table 5.4: Potentially Inappropriate Medications pre- Vs post-Hospitalisation (N=240)	91
Table 5.5: Changes in PIM after hospitalisation as expressed by the number of patients	93

Table 5.6: Potentially Prescribing Omissions pre- Vs post-Hospitalisation (N=240)	94
Table 6.1: Rating the knowledge scale items in terms of their relevance to the tested domain by the expert panel	104
Table 6.2: Reliability test of the final knowledge scale items	104
Table 6.3: Characteristics of the participants (N = 82)	105
Table 6.4: Confidence and practices of the physicians and pharmacists regarding geriatric patients (N = 82)	106
Table 6.5: Percentages of respondents who answered vignettes correctly (N = 82)	108
Table 6.6: Comparison of knowledge scores based on participants' characteristics	108
Table 6.7: Barriers to appropriate prescribing, with the number (percentage) of participants who cited the barrier in descending order.	110
Table 7.1: Specifying the target behaviour	119
Table 7.2: Behavioural analysis	120
Table 7.3: Matrix of links between COM-B and intervention functions. Used with permission from (Michie et al., 2016)	121
Table 7.4: Identifying the intervention techniques	122
Table 7.5: Characteristics of the participants (N = 29)	125
Table 7.6: Number (percentage) of participants who correctly answered the vignettes (N = 29).	126
Table 8.1: Characteristics of the study population (N: 480)	135
Table 8.2: Comparison of prevalence rates of PIMs among control and intervention groups	136
Table 8.3: Comparison of the prevalence rate of PPO among control and intervention groups	139
Table 8.4: The predictors of having PPO at discharge in the study population	140

LIST OF FIGURES

<u>Figure No.</u>	<u>Page No.</u>
Figure 3.1: Distribution of PIMs among patients	52
Figure 3.2: Distribution of PPOs among patients	56
Figure 4.1: Included and excluded patients	70
Figure 4.2: Frequency of reported problems by patients as per EQ-5D dimensions (n: 502).	73
Figure 7.1: The behaviour change wheel. Used with permission from (Michie et al., 2011)	118
Figure 7.2: COM-B system. Used with permission from (Michie et al., 2011)	118
Figure 7.3: Screenshot of searching for captopril-related recommendations on Plus65 Med©	123
Figure 8.1: Distribution of PIMs among the two groups	136
Figure 8.2: Distribution of PPOs among the study groups	138

LIST OF ABBREVIATIONS

AC-CCI	Age combined Charlson Comorbidity Index
ACE	Angiotensin-converting enzyme
ADL	Patients' activities of daily living
ADR	Adverse drug reaction
App	Application
ARB	Angiotensin receptor blocker
BCW	Behaviour change wheel
CAD	Coronary artery diseases
CCB	Calcium channel blocker
CDSS	Clinical decision support software/computerised decision support system
CGA	Comprehensive geriatric assessment
CGE	Continuous medical education
COM-B	Capability, opportunity and motivation behaviour
CMR	Clinical medication review
CPOE	Computerised physician/prescriber order entry
CRC	Clinical Research Center
DRP	Drug related problem
EUGMS	European Union Geriatric Medicine Society
GABA	Gamma-aminobutyric acid
GP	General practitioners
HCP	Healthcare provider/professionals
HMR	Home medication review
HRQOL	Health-related quality of life
I-CVI	Content validity index for items
INR	International normalized ratio
IQR	Interquartile range
IT	Information technology
MAI	Medication appropriateness index
MDT	Multidisciplinary team
NSAIDs	Nonsteroidal anti-inflammatory drugs
PIM	Potentially inappropriate medication
PIP	Potentially inappropriate prescribing
PPI	Proton pump inhibitor
PPO	Potentially prescribing omission
QoL	Quality of life
RCT	Randomised controlled trial
S-CVI/Ave	Average content validity index for scale
SD	Standard deviation
SPRM	Structured pharmacist review of medication
START	Screening Tool to Alert doctors to Right Treatment
STOPP	Screening Tool of Elderly Persons' potentially inappropriate Prescription
TCA	Tricyclic antidepressants

CHAPTER ONE

INTRODUCTION

1.1 BACKGROUND

The use of medication consists of five consecutive steps; prescribing, communicating orders, dispensing, administering, and monitoring. Errors associated with potential risks may occur at each step, and several preventable actions can be taken at prescribing level where medications might be prescribed inappropriately (Page et al., 2010). Inappropriate prescribing is demonstrated to be associated with adverse drug reactions (ADRs) (Hamilton et al., 2011), increase in hospitalisation (Dalleur et al., 2012; van der Stelt et al., 2016), decrease in patients' adherence (Mansur et al., 2009), and healthcare resource wastage (Cahir et al., 2014; Morgan et al., 2016).

Potentially inappropriate prescribing (PIP) occurs when there is a prescribing of a potentially inappropriate medication (PIM), where the risks associated with the medication outweigh the expected benefits, or when there is a potentially prescribing omission (PPO), where a specific medication is indicated but not prescribed (Hill-Taylor et al., 2016; O'Connor, Gallagher, & O'Mahony, 2012).

The mean age of the global population is consistently increasing as the quality of health services keeps on improving. It is expected that the number of elderly people will reach more than 70 million by 2030 which is double that recorded in 2000 (Amanda H. Lavan, Gallagher, & O'Mahony, 2016). Alarmingly, inappropriate prescribing is quite common among elderly people whom are the largest consumers of medications (Jetha, 2015). These people are more vulnerable to drug-related problems (DRPs) and negative outcomes associated with inappropriate prescribing due to the presence of multiple

comorbidities, polypharmacy and age-related pharmacokinetic and pharmacodynamic alterations (O'Connor et al., 2012).

1.2 DEFINITION OF THE ELDERLY PERSON

In fact, there is no consensus definition for elderly people. The UN agreed cutoff is 60+ years to refer to the elderly people. As the age of 60 or 65 is the retirement age in most countries, it was stated that this age is the beginning of old age. Most developed countries have stated the chronological age of 65 years as a definition of “elderly” or elderly person (UNPFA, 2012). In medical literature, elderly people are conventionally defined as those aged 65 years and over (Patterson, Hughes, Kerse, Cardwell, & Bradley, 2012). As most of the criteria for appropriate prescribing in elderly people were developed to be used in patients ≥ 65 years old (Basger, Chen, & Moles, 2008; O'Mahony et al., 2015; Samuel, 2015), the current study used the age of 65 years old as a cutoff to refer to elderly people. According to the Oxford English dictionary, the word “geriatric” is a noun and adjective that means older person or relating to older people, especially with regard to their healthcare (Simpson & Weiner, 1989). In the current study, the term “elderly people” was used to refer to general people who are ≥ 65 years old, and the term “geriatric patients” was used to refer to patients who are ≥ 65 years old.

1.3 CHANGES WITH AGEING

1.3.1 Changes in Pharmacokinetics of Drugs in Elderly People

Realisation of pharmacokinetic differences of medications is essential to design a proper drug dosing regimen for every patient. Age-related changes in all phases of drug pharmacokinetics should be taken into consideration when prescribing for geriatric

patients. These changes are results of reduced functions of several organs and decreased ability of homeostatic mechanisms with age (Corsonello, Pedone, & Incalzi, 2010).

1.3.1.1 Absorption

Several changes were reported to occur in the gastrointestinal (GI) tract with advancing age that may account for alterations in the rate and extent of drug absorption. In elderly people, gastric acid production decreases which results in increased gastric pH. In addition, salivation, absorption surface area, splanchnic blood flow, small intestine's absorptive capability, peristalsis, gastric emptying and colonic transit are all decreased with advancing age (Corsonello et al., 2010; Duraković & Vitezić, 2013).

Regardless of the relatively large number of age-related changes in the GI tract, a limited number of drugs are affected by these changes. This is due to the fact that most drugs are absorbed by passive transport which is not affected by the mentioned changes. However, age-related altered absorption may be clinically important. For example, the bioavailability of some antiepileptic drugs may be influenced by advancing age resulting in altered plasma concentrations of these narrow-therapeutic index agents (Gidal, 2006). On the other hand, decreased first-pass effect associated with advancing age results in increased bioavailability of morphine and some other drugs (Emily R. Hajjar et al., 2014). Decreased gastric emptying and colonic transit lead to delayed absorption of most drugs. This change may be of importance when fast onset and early achievement of maximum concentration are required. However, it has no clinical effect on chronic medications once the steady state concentration is achieved.

1.3.1.2 Distribution

Total body fat increases, whilst muscle (lean body) mass and total body water decrease in elderly people. Therefore, the volume of distribution of lipophilic drugs (e.g., diazepam) increases resulting in possible prolonged half-life and extended clearance of these medications (Hutchison & O'Brien, 2007). Additionally, this may reduce the availability of some drugs that excessively distribute to fat tissue (e.g., vitamin D) in the circulating blood. Reduced vitamin D may put geriatric patients -particularly women- at higher risk for negative clinical consequences like fractures (Corsonello et al., 2010). On the other hand, hydrophilic drugs (e.g., aminoglycosides) have a smaller volume of distribution in elders compared with younger people which result in an increase in their plasma concentration and thus lower than normal loading dose may be required (Corsonello et al., 2010; Emily R. Hajjar et al., 2014).

Plasma albumin levels also reduce in geriatric patients - particularly acutely ill patients- which increases free (unbound) fraction of acidic medications (e.g., warfarin) that highly bound to plasma albumin (Duraković & Vitezić, 2013). As the free fraction of a drug is the responsible fraction for the pharmacological effects, increasing unbound drug concentration may increase side effects and toxicity of highly protein-bound drugs (Duraković & Vitezić, 2013; Hutchison & O'Brien, 2007). However, in such cases, the body usually increases the clearance of these drugs as a compensating mechanism to avoid harmful effects of the increased pharmacological action (Emily R. Hajjar et al., 2014). This makes the age-related albumin change clinically insignificant except during early stage of drug therapy until drug's steady-state equilibrium takes place. In addition, this issue should be taken into consideration when interpreting of free concentrations of such drugs (Hutchison & O'Brien, 2007). Basic medications (e.g., imipramine) bind in the human body to α 1-acid glycoprotein which increases in elderly people. This reduces

the concentration of the free drug and may lessen the pharmacological effects of some basic drugs (Hutchison & O'Brien, 2007).

P- glycoprotein is a cell membrane active efflux pump that contributes to the active drug transportation. There is evidence of reduction of P- glycoprotein activity in elderly people which notably influences the drug transportation across the blood-brain barrier (BBB). This exposes the brain of elderly people to higher than normal amount of medications leading to accumulation of medications in the brain and greater cerebral side effects (Corsonello et al., 2010; Emily R. Hajjar et al., 2014).

1.3.1.3 Metabolism

There are decreases in liver volume and hepatic blood flow by up to 30% and 50%, respectively in elderly people (Corsonello et al., 2010; Hutchison & O'Brien, 2007). Bioavailability of medications that undergo extensive first-pass metabolism (e.g. morphine and verapamil) may significantly increase and therefore, lower than normal doses should be used (Hutchison & O'Brien, 2007). In contrast, the bioavailability of prodrugs like some angiotensin converting enzyme (ACE) inhibitors decreases in geriatric patients as these medications need the first pass metabolism to be converted into active ingredients (Corsonello et al., 2010). Phase I reactions (oxidation, reduction and hydrolysis) are more diminished with age than phase II reactions. It is believed that the reduction in phase I metabolism is more attributed to the decrease in liver mass than to the reduced enzyme activity. The clearance of medications that extensively metabolised by phase-I reactions like diazepam and theophylline, decreases and their half-lives increase, so their doses need to be lowered (Emily R. Hajjar et al., 2014). As phase II metabolism is not significantly affected with age, medications that are

metabolised mainly through this pathway are considered as safer alternatives in geriatric patients compared to those extensively metabolised by phase I reactions.

1.3.1.4 Elimination

Advancing age associates with an impaired renal function which is related to the reduction in kidney mass, renal blood flow and glomerular filtration in elderly people. However, it is difficult to distinguish between the effect of advancing age per se on renal function and the impact of age-related diseases and polypharmacy. These changes reduce the elimination of medications that extensively excreted by the kidneys (e.g., aminoglycoside, ACE inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs) digoxin, lithium, and vancomycin). Therefore, the half-lives of these medications are prolonged which leads to an increase in the incidence of ADRs in geriatric patients (Corsonello et al., 2010; Emily R. Hajjar et al., 2014; Mangoni & Jackson, 2003)

Creatinine clearance serves as a representative of renal glomerular filtration and hence it is considered as an indicator of the renal function. No specific formula is established for elderly people to calculate their creatinine clearance. Although several equations were proposed for calculating creatinine clearance, Cockcroft Gault equation (Cockcroft & Gault, 1976) is still the standard formula for dose adjustment of renally-eliminated drugs in elderly people (Emily R. Hajjar et al., 2014; Hutchison & O'Brien, 2007):

$$\text{Creatinine Clearance (mL/min)} = \frac{(140 - \text{age}) \times \text{weight (kg)}}{\text{serum creatinine } \left(\frac{\mu\text{mol}}{\text{L}}\right)} \times \text{constant}$$

Where: The constant is 1.04 for females and 1.23 for males.

For obese patients (patients with body mass index ≥ 30), it is suggested to use the lean body weight since muscles are the source of creatinine in the body. Another

option is to use Salazar Corcoran formula (Salazar & Corcoran, 1988) for calculating creatinine clearance for obese people.

1.3.2 Changes in Pharmacodynamics of Drugs in Elderly People

Ageing is associated with pharmacodynamic changes that may clinically affect the therapeutic response to several medications independently of age-related pharmacokinetic alterations. In contrast to pharmacokinetic changes, pharmacodynamic changes could not be predicted or quantified (Corsonello et al., 2010). The changes in drug response in geriatric patients may be due to changes in number and affinity of receptors, post-receptor signal transduction and deterioration in homeostatic response in geriatric patients (Emily R. Hajjar et al., 2014). These pharmacodynamic changes - in addition to pharmacokinetic alterations- further complicate the prescribing in geriatric patients. Various body systems are affected by these changes, and therapeutic adjustment may be required in certain cases.

1.3.2.1 Central Nervous System

Multiple physiological changes occur in the brain of elderly people. These changes are complex and involve different regions of the brain by different mechanisms including alteration in the number of neurons and receptors, changes in the neurotransmitters and hormonal shifts (gender and growth hormones). Additionally, age-related impairment of BBB permeability increases the concentration of many drugs in the brain. Changes in medications that affect gamma-aminobutyric acid (GABA), cholinergic and dopaminergic systems in the brain are the most prominent and studied medications (Corsonello et al., 2010; Hutchison & O'Brien, 2007).

1.3.2.1.1 Changes of Responsiveness to Benzodiazepines

The exact mechanism of increased effect of benzodiazepines in elderly is unclear (Corsonello et al., 2010; Mangoni & Jackson, 2003). A proposed mechanism is the age-related changes in the GABA system which may increase the sensitivity of geriatric patients to benzodiazepines (Hutchison & O'Brien, 2007). For instance, it was found that the half maximal effective concentration (EC50) of midazolam and flunitrazepam in elderly people is half of that in young adults regardless the absence of pharmacokinetic changes of these medications with age (Corsonello et al., 2010). Therefore, geriatric patients are at higher risk to experience ADRs of benzodiazepines. This is clinically significant as the aggravated hypnotic effect of benzodiazepines is associated with falls and consequently hip fractures (de Jong, Van der Elst, & Hartholt, 2013).

1.3.2.1.2 Changes in Responsiveness to Cholinergic Medications

Several changes in the cholinergic system have been reported to be associated with advancing age. There is a decrease in 1) number of cholinergic neurons; 2) choline uptake from the periphery; 3) choline acetyltransferase levels and 4) cholinergic receptors. Also, the levels of acetylcholinesterase are increased (Hutchison & O'Brien, 2007). These alterations lead to increase the CNS sensitivity to the anticholinergic effects of medications such as sedation, drowsiness, urinary retention, constipation, tachycardia, and confusion. Widespread drug classes are demonstrated to have anticholinergic effects like antispasmodics, bronchodilators, antihistamines, skeletal muscle relaxants, and antipsychotic drugs (Collamati et al., 2016). Because of that, the anticholinergic burden should be considered when prescribing multiple drugs with anticholinergic effects for geriatric patients.